Novo Nordisk's New Oral Anti-Inflammatory Candidate Clears First Human Study Milestone
Grupo Santander Starts Novo Nordisk Coverage at Outperform
La Fundación OMS Y Novo Nordisk Amplían Su Colaboración Para El Apoyo Financiero a Los Sistemas De Salud
Lilly Eyes $3B Investment in China as It Seeks Approval for Weight Loss Pill
Hims & Hers Hires Former Lilly Communications Chief
Dow Jones Top Company Headlines at 5 PM ET: Oracle Raises 2027 Sales Outlook Amid AI Demand, Restructuring | Bill ...
Novo Nordisk Stock (NVO) Dives After FDA Scolds the Pharma Giant
Novo Nordisk A/S (NVO) Expands Manufacturing to Support Rising Global Demand for GLP-1 Drugs
Sector Update: Health Care Stocks Mixed Tuesday Afternoon
8 Health Care Stocks With Whale Alerts In Today's Session
Lindt Says GLP-1 Users Are Eating More Chocolate, Hershey Not so Sure
GLP-1 Weight-loss Drug Race Heats up as New Rival Matches Wegovy Results With Fewer Side Effects | NYSE:NVO
Hims & Hers Upgraded to Buy From Hold at Needham
BMO Capital Maintains Novo-Nordisk A/S(NVO.US) With Hold Rating, Maintains Target Price $45
Today's Analyst Rating | J.P. Morgan Cuts Its Price Target Cut on Oracle to $230, TD Cowen Downgrades Novo-Nordisk A/S to Hold
Wall Street analysts updated their ratings today including $Oracle(ORCL.US)$ and $Novo-Nordisk A/S(NVO.US)$, according to TipRanks.
Analysts Have Conflicting Sentiments on These Healthcare Companies: Novo Nordisk (NVO) and Hinge Health, Inc. Class A (HNGE)
Lilly Says GLP-1 Access for Some Medicare Members Could Exceed $50 Monthly Cap
Citi has upgraded Hims & Hers Health (HIMS.US) to 'Neutral', citing a compliance premium under the Novo-Nordisk A/S agreement.
Citigroup upgraded the rating of Hims & Hers Health from 'Sell' to 'Neutral' and significantly raised the target price from $13.25 to $24.
TD Cowen Downgrades Novo-Nordisk A/S(NVO.US) to Hold Rating, Cuts Target Price to $42
Analysts' Opinions Are Mixed on These Healthcare Stocks: Neurosense Therapeutics Ltd. (NRSN) and Novo Nordisk (NVO)